Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein-Barr virus-specific T cell therapy: interim results of a phase I trial

Michael P. Pender(The University of Queensland), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Corey Smith(QIMR Berghofer Medical Research Institute), Peter A. Csurhes(The University of Queensland), Alan Coulthard(Mental Health Research Institute), Zara A. Ioannides(The University of Queensland), Kate Thompson(The University of Queensland), Stefan Blum, Scott R. Burrows(QIMR Berghofer Medical Research Institute), Nanette L. Douglas(The University of Queensland), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Kaye D. Hooper(The University of Queensland), Kerryn Green, Leone Beagley, Tracey Hopkins(Royal Brisbane and Women's Hospital), Sweera Rehan(QIMR Berghofer Medical Research Institute)
Queensland's institutional digital repository (The University of Queensland)
January 1, 2017
Cited by 0

Related Papers

Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
|New England Journal of Medicine|2018|856
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
|Blood|2006|250
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235